Expert Review of Anticancer Therapy最新文献_第8页

Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives. 三阴性乳腺癌的放射治疗：从分子洞察到临床视角。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-03-21 DOI: 10.1080/14737140.2024.2333320

Jongmyung Kim, Veronia Fahmy, Bruce G Haffty

{"title":"Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives.","authors":"Jongmyung Kim, Veronia Fahmy, Bruce G Haffty","doi":"10.1080/14737140.2024.2333320","DOIUrl":"10.1080/14737140.2024.2333320","url":null,"abstract":"Introduction: Triple-negative breast cancer (TNBC) lacks three common receptors, making traditional treatments less effective. This review highlights the importance of radiotherapy and emerging therapeutic strategies to enhance treatment outcomes in TNBC.Areas covered: We conducted a literature search on PubMed for publications from 2000 to 2023 to discuss the critical role of radiotherapy in managing TNBC, emphasizing its applications from locoregional control to improving survival rates. The review explores molecular mechanisms underlying TNBC's radiotherapy response, including DNA damage repair and apoptosis, with a focus on BRCA1/2 mutations and Poly (ADP-ribose) polymerase (PARP) inhibition. We summarize preclinical and clinical research on radiosensitization strategies, from gene-targeted therapies to immunotherapy combinations, and the impact of post-mastectomy radiation therapy on locoregional control. The potential of personalized treatment approaches, integrating molecular profiling, targeted radiosensitizers, and the synergistic effects of radiotherapy with immunotherapy, is also discussed.Expert opinion: Future TNBC treatment strategies should focus on precision medicine, integrating immunotherapy, developing novel radiosensitizers, and targeting biological pathways to overcome radioresistance. The integration of radiomics and artificial intelligence offers promising avenues for enhancing treatment personalization and efficacy, aiming to improve patient outcomes in TNBC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"211-217"},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review. 光动力疗法联合化疗治疗宫颈癌的最新进展：系统综述。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-04-02 DOI: 10.1080/14737140.2024.2337259

Lucimara Rodrigues Carobeli, Ana Beatriz Camillo Santos, Laura Beatriz Marques Martins, Edilson Damke, Marcia Edilaine Lopes Consolaro

{"title":"Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review.","authors":"Lucimara Rodrigues Carobeli, Ana Beatriz Camillo Santos, Laura Beatriz Marques Martins, Edilson Damke, Marcia Edilaine Lopes Consolaro","doi":"10.1080/14737140.2024.2337259","DOIUrl":"10.1080/14737140.2024.2337259","url":null,"abstract":"Introduction: Despite the evidence that photodynamic therapy (PDT) associated with chemotherapy presents great potential to overcome the limitations of monotherapy, little is known about the current status of this combination against cervical cancer. This systematic review aimed to address the currently available advances in combining PDT and chemotherapy in different research models and clinical trials of cervical cancer.Methods: We conducted a systematic review based on PRISMA Statement and Open Science Framework review protocol using PubMed, Web of Science, Embase, Scopus, LILACS, and Cochrane databases. We selected original articles focusing on 'Uterine Cervical Neoplasms' and 'Photochemotherapy and Chemotherapy' published in the last 10 years. The risk of bias in the studies was assessed using the CONSORT and SYRCLE tools.Results: Twenty-three original articles were included, focusing on HeLa cells, derived from endocervical adenocarcinoma and on combinations of several chemotherapeutics. Most of the combinations used modern drug delivery systems for improved simultaneous delivery and presented promising results with increased cytotoxicity compared to monotherapy.Conclusion: Despite the scarcity of animal studies and the absence of clinical studies, the combination of chemotherapy with PDT presents a potential option for cervical cancer therapy requiring additional studies.Osf registration: https://doi.org/10.17605/OSF.IO/WPHN5 [Figure: see text].","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"263-282"},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis. 卡博替尼治疗恶性肿瘤的疗效和安全性比较：系统综述和荟萃分析。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-04-01 DOI: 10.1080/14737140.2024.2337266

Jingyang Su, Cui Ni, Yuqian Wu, Jialin Zhang, Zelin Cai, Jinhua Lu, Shengyou Lin, Jue Wang

{"title":"Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis.","authors":"Jingyang Su, Cui Ni, Yuqian Wu, Jialin Zhang, Zelin Cai, Jinhua Lu, Shengyou Lin, Jue Wang","doi":"10.1080/14737140.2024.2337266","DOIUrl":"10.1080/14737140.2024.2337266","url":null,"abstract":"Objectives: To provide a more comprehensive understanding of the efficacy and safety profile of cabozantinib versus placebo in malignant tumors, we conducted a systematic review and meta-analysis. This involved analyzing a collection of published randomized controlled trials to assess the outcomes.Methods: We used RevMan5.3 software to evaluate the outcomes of the collected studies. The primary outcome we focused on was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and disease control rate (DCR).Results: Our findings revealed that compared to placebo, cabozantinib significantly extended the PFS of patients [hazard ratios (HR) 0.37, 95% confidence intervals (CI): 0.32, 0.43, p < 0.00001]. Additionally, cabozantinib improved the OS of patients [HR 0.78, 95%CI: 0.68, 0.91, p = 0.002]. While it is important to note that cabozantinib was associated with a higher likelihood of causing digestive, cutaneous, and cardiovascular related adverse events [relative risk (RR) 4.40, 95% CI: 3.10, 6.25, p < 0.00001].Conclusion: Based on our analysis, cabozantinib significantly prolonged the PFS and OS of patients with malignant tumors (p < 0.01). We recommend the use of cabozantinib in treating advanced malignant tumors. However, it is important to continuously monitor and manage the drug-related adverse events.Registration: PROSPERO (No. CRD42023449261).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"293-302"},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic colorectal cancer- third line therapy and beyond. 转移性结直肠癌--三线治疗及以后。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-04-03 DOI: 10.1080/14737140.2024.2334784

Tiffany Foo, Amitesh Roy, Christos Karapetis, Amanda Townsend, Timothy Price

引用次数: 0

Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis. 尼妥珠单抗联合伊匹单抗与单用尼妥珠单抗治疗晚期黑色素瘤患者的疗效和安全性：系统综述和荟萃分析。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-03-29 DOI: 10.1080/14737140.2024.2336106

Shuting Cui, Xiaozhe Sun, Junxi Gao

{"title":"Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis.","authors":"Shuting Cui, Xiaozhe Sun, Junxi Gao","doi":"10.1080/14737140.2024.2336106","DOIUrl":"10.1080/14737140.2024.2336106","url":null,"abstract":"Background: Annual melanoma incidence in the US is escalating.Objective: Comprehensive evaluation of nivolumab alone or with ipilimumab for advanced melanoma treatment.Research design and methods: A systematic search was conducted across PubMed, Embase, Web of Science, and Cochrane databases, extending until August 2023. A range of outcomes were evaluated, encompassing overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), disease-free survival (DFS), adverse events (both any and serious), complete response rate, mortality rate, and recurrence rate in patients with advanced melanoma.Results: This analysis was conducted on seven relevant studies, involving 2,885 patients. The baseline characteristics of both groups were found to be comparable across all outcomes, with the exception of tumor size. The pooled analysis did not reveal any significant disparities, except for PFS, where the nivolumab-ipilimumab treatment group demonstrated a significantly longer PFS compared to the nivolumab group. However, there was a notable discrepancy in any adverse events (Odds Ratio (OR): 2.69; 95% Confidence Interval (CI): 1.96, 3.69; p < 0.00001) and serious adverse events (OR: 3.59; 95% CI: 2.88, 4.49, p < 0.00001) between the two groups, suggesting that the safety profile of nivolumab combined with ipilimumab was inferior.Conclusions: Given diversity and potential biases, oncologists should base immunotherapy decisions on professional expertise and patient characteristics.Registration: PROSPERO registration number: CRD42023453484.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"283-291"},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors. 接受新型雄激素受体抑制剂治疗的非转移性去势抵抗性前列腺癌（nmCRPC）患者的药物相互作用潜力。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-03-12 DOI: 10.1080/14737140.2024.2328778

Sreevalsa Appukkuttan, Gilbert Ko, Chunmay Fu, Breyanne Bannister, Sheldon X Kong, Jay Jhaveri, Stephen J Freedland

{"title":"Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.","authors":"Sreevalsa Appukkuttan, Gilbert Ko, Chunmay Fu, Breyanne Bannister, Sheldon X Kong, Jay Jhaveri, Stephen J Freedland","doi":"10.1080/14737140.2024.2328778","DOIUrl":"10.1080/14737140.2024.2328778","url":null,"abstract":"Background: Nonmetastatic castration-resistant prostate cancer (nmCRPC) patients are often older and use concurrent medications that increase the potential for drug-drug interactions (pDDIs). This study assessed pDDI prevalence in real-world nmCRPC patients treated with apalutamide, darolutamide, or enzalutamide.Research design and methods: Castrated prostate cancer patients without metastases prior to androgen receptor inhibitor initiation were identified retrospectively via Optum Clinformatics Data Mart claims data (8/2019-3/2021). The top 100 concomitant medications were assessed for pDDIs.Results: Among 1,515 patients (mean age: 77 ± 8 years; mean Charlson Comorbidity Index: 3 ± 3), 340 initiated apalutamide, 112 darolutamide, and 1,063 enzalutamide. Common concomitant medication classes were cardiovascular (80%) and central nervous system (52%). Two-thirds of the patients received ≥5 concomitant medications; 30 (30/100 medications) pDDIs were identified for apalutamide and enzalutamide each and 2 (2/100 medications) for darolutamide. Most pDDIs had risk ratings of C or D, but four for apalutamide were rated X. Approximately 58% of the patients on apalutamide, 5% on darolutamide, and 54% on enzalutamide had ≥1 identified pDDI.Conclusions: Results showed a higher frequency of pDDIs in patients receiving apalutamide and enzalutamide vs darolutamide. The impact of these could not be determined retrospectively. DDI risk should be carefully evaluated when discussing optimal therapy for patients with nmCRPC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"325-333"},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies 利用已发表的比较研究对治疗 3L+ R/R LBCL 的 CAR T 细胞疗法进行网络荟萃分析

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-04-22 DOI: 10.1080/14737140.2024.2343801

Olalekan O. Oluwole, Sattva S. Neelapu, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Sally W. Wade, Steve Kanters, Anik R. Patel, Frederick L. Locke

引用次数: 0

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: Elacestrant as the poster-child. 针对激素受体阳性乳腺癌的新型口服选择性雌激素受体降解剂（SERDs）：以艾乐司群为代表。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-04-20 DOI: 10.1080/14737140.2024.2346188

Jennifer C Keenan, Arielle J Medford, Charles S Dai, Seth A Wander, Laura M Spring, Aditya Bardia

引用次数: 0

Navigating resistance to ALK inhibitors in the Lorlatinib Era: a comprehensive perspective on NSCLC. Lorlatinib时代的ALK抑制剂耐药性导航：NSCLC的综合视角。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-04-17 DOI: 10.1080/14737140.2024.2344648

Maria Gemelli, Adriana Albini, Gianpiero Catalano, Matteo Incarbone, Maria Cannone, Emanuela Balladore, Riccardo Ricotta, Giuseppe Pelosi

引用次数: 0

The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis 肝细胞癌患者的年龄、性别和东部合作肿瘤学组表现状态对免疫检查点抑制剂疗效和安全性的影响：系统综述和荟萃分析

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-04-16 DOI: 10.1080/14737140.2024.2341723

Cheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Guo-Qiang Pan, Xiao Zhang, Xin-Chen Mao, Si-Yu Tan, Rui-Zhe Li, Dong-Xu Wang, Zhao-Ru Dong, Yu-Chuan Yan, Tao Li

引用次数: 0